TVTX Q3 2022 Earnings — Travere Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TVTXTravere Therapeutics, Inc.

$3B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$53M-21.6% YoY

Gross Profit

$52M96.9% margin

Operating Income

-$65M-121.4% margin

Net Income

-$70M-130.2% margin

EPS (Diluted)

$-1.09

QoQ Revenue Growth

-1.2%

Cash Flow

Operating Cash Flow

-$40M

Free Cash Flow

-$40M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$726M

Total Liabilities

$626M

Stockholders' Equity

$101M

Cash & Equivalents

$151M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$53M	$68M	-21.6%
Gross Profit	$52M	$67M	-22.2%
Operating Income	-$65M	-$32M	-104.8%
Net Income	-$70M	-$36M	-95.4%

Revenue Segments

Product

$51M50%

Bile Acid Products

$25M25%

Tiopronin Products

$25M25%